Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1976 1
1977 3
1978 1
1979 4
1980 3
1981 11
1982 3
1983 6
1984 13
1985 10
1986 17
1987 7
1988 17
1989 20
1990 19
1991 18
1992 11
1993 20
1994 16
1995 23
1996 24
1997 26
1998 24
1999 30
2000 26
2001 42
2002 38
2003 47
2004 39
2005 45
2006 53
2007 49
2008 33
2009 35
2010 62
2011 64
2012 64
2013 73
2014 59
2015 63
2016 78
2017 76
2018 59
2019 44
2020 48
2021 62
2022 73
2023 60
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,495 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation.
Perreault S, Côté R, Dragomir A, White-Guay B, Lenglet A, Dorais M. Perreault S, et al. PLoS One. 2022 Dec 1;17(12):e0277744. doi: 10.1371/journal.pone.0277744. eCollection 2022. PLoS One. 2022. PMID: 36454798 Free PMC article.
No significant difference was observed in the incidence of comparative stroke/SE and MB between low-dose and standard-dose rivaroxaban, except for the risk of acute myocardial infarction (AMI), which was increased with the low dose in the UT analysis. …
No significant difference was observed in the incidence of comparative stroke/SE and MB between low-dose and standard-dose riv …
A Case-Control Study of the Dose-Response Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Acute Myocardial Infarction.
Zhao M, Zhao D, Li Y, Wang X, Yi B, Zhou B. Zhao M, et al. Front Cardiovasc Med. 2022 Feb 28;9:823381. doi: 10.3389/fcvm.2022.823381. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35295269 Free PMC article.
According to the dose-response curve, the risk of AMI increased significantly with an increase of serum TAFI concentration (P = 0.0387). CONCLUSION: Acute myocardial infarction patients had higher serum TAFI levels, and TAFI was an independent risk factor for AMI …
According to the dose-response curve, the risk of AMI increased significantly with an increase of serum TAFI concentration (P …
High-dose intramyocardial HMGB1 induces long-term cardioprotection in sheep with myocardial infarction.
Bauzá MDR, Giménez CS, Locatelli P, De Lorenzi A, Hnatiuk A, Capogrossi MC, Crottogini A, Cuniberti L, Olea FD. Bauzá MDR, et al. Drug Deliv Transl Res. 2019 Oct;9(5):935-944. doi: 10.1007/s13346-019-00628-z. Drug Deliv Transl Res. 2019. PMID: 30859393
Given the lack of data in large mammals, we searched the dose that would promote angiogenesis and expression of specific regenerative genes in sheep with AMI (protocol 1) and, subsequently, use this dose to study long-term effects on infarct size and left ven …
Given the lack of data in large mammals, we searched the dose that would promote angiogenesis and expression of specific regenerative …
Neuropeptide Y attenuates cardiac remodeling and deterioration of function following myocardial infarction.
Qin YY, Huang XR, Zhang J, Wu W, Chen J, Wan S, Yu XY, Lan HY. Qin YY, et al. Mol Ther. 2022 Feb 2;30(2):881-897. doi: 10.1016/j.ymthe.2021.10.005. Epub 2021 Oct 8. Mol Ther. 2022. PMID: 34628054 Free PMC article.
We found that AMI mice lacking NPY developed more severe AMI than WT mice with worse cardiac dysfunction, progressive cardiac inflammation and fibrosis, and excessive apoptosis but impairing angiogenesis. All of these changes were reversed when the NPY KO mice were …
We found that AMI mice lacking NPY developed more severe AMI than WT mice with worse cardiac dysfunction, progressive cardiac …
Prognostic Impact of beta-Blocker Dose After Acute Myocardial Infarction.
Hwang D, Lee JM, Kim HK, Choi KH, Rhee TM, Park J, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon HC, Jeong MH, Kim HS; KAMIR Investigators. Hwang D, et al. Circ J. 2019 Jan 25;83(2):410-417. doi: 10.1253/circj.CJ-18-0662. Epub 2018 Nov 22. Circ J. 2019. PMID: 30464110 Free article.
BACKGROUND: The differential prognostic impact of beta-blocker dose after acute myocardial infarction (AMI) has been under debate. ...These patients were classified into 3 groups (no beta-blocker; low-dose [<25% of target dose]; and high-dose …
BACKGROUND: The differential prognostic impact of beta-blocker dose after acute myocardial infarction (AMI) has been under deb …
Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial.
Shirakawa T, Fujisue K, Nakamura S, Yamamoto N, Oshima S, Matsumura T, Tsunoda R, Hirai N, Koide S, Tayama S, Kikuta K, Hirose T, Maruyama H, Fujimoto K, Kajiwara I, Sakamoto T, Nakao K, Sakaino N, Nagayoshi Y, Hokamaki J, Shimomura H, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Ogawa H, Tsujita K. Shirakawa T, et al. J Atheroscler Thromb. 2022 Feb 1;29(2):229-241. doi: 10.5551/jat.59477. Epub 2021 Jan 7. J Atheroscler Thromb. 2022. PMID: 33408315 Free PMC article. Clinical Trial.
AIM: Matrix metalloproteinases (MMPs) play critical roles in acute myocardial infarction (AMI). This trial was conducted to determine the potential effects of higher-dose rosuvastatin on circulating MMP levels in patients with AMI. ...RESULTS: Between August …
AIM: Matrix metalloproteinases (MMPs) play critical roles in acute myocardial infarction (AMI). This trial was conducted to determine …
Personalized Medicine: Pharmacogenomics and Drug Development.
Mirsadeghi S, Larijani B. Mirsadeghi S, et al. Acta Med Iran. 2017 Mar;55(3):150-165. Acta Med Iran. 2017. PMID: 28282716 Free article. Review.
Personalized medicine aims is to supply the proper drug to the proper patient within the right dose. Pharmacogenomics (PGx) is to recognize genetic variants that may influence drug efficacy and toxicity. ...
Personalized medicine aims is to supply the proper drug to the proper patient within the right dose. Pharmacogenomics (PGx) is to rec …
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW. Jeong YH, et al. Circ Cardiovasc Interv. 2010 Feb 1;3(1):17-26. doi: 10.1161/CIRCINTERVENTIONS.109.880179. Epub 2010 Jan 26. Circ Cardiovasc Interv. 2010. PMID: 20118150 Clinical Trial.
BACKGROUND: Optimal platelet inhibition is an important therapeutic adjunct in patients acute myocardial infarction (AMI) undergoing coronary stenting. Whether adjunctive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) can inhibit enhanced platelet re …
BACKGROUND: Optimal platelet inhibition is an important therapeutic adjunct in patients acute myocardial infarction (AMI) undergoing …
Clinical outcomes of adjusted-dose versus standard-dose prasugrel in East Asian patients with acute myocardial infarction.
Honda S, Lee S, Cho KH, Takegami M, Nishihira K, Kojima S, Asaumi Y, Saji M, Yamashita J, Hibi K, Takahashi J, Sakata Y, Takayama M, Sumiyoshi T, Ogawa H, Kimura K, Sim DS, Kim HK, Kim W, Ahn Y, Jeong MH, Yasuda S. Honda S, et al. Int J Cardiol. 2024 May 30:132197. doi: 10.1016/j.ijcard.2024.132197. Online ahead of print. Int J Cardiol. 2024. PMID: 38823533 Free article.
This study aimed to comparatively assess the ischaemic and bleeding outcomes of adjusted-dose (maintenance dose: 3.75 mg) and standard-dose (maintenance dose: 10 mg) prasugrel in East Asian patients with AMI undergoing PCI. METHODS: From a combi …
This study aimed to comparatively assess the ischaemic and bleeding outcomes of adjusted-dose (maintenance dose: 3.75 mg) and …
1,495 results